(Q37536874)

English

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.

scientific article published on 30 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

quality of life

1 reference

based on heuristic

inferred from title

George Tomlinson

object named as

George Tomlinson

2

0 references

object named as

Murray D Krahn

9

0 references

6

object named as

Audrey Laporte

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

4

object named as

Mel Krajden

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Priscilla C Hsu

3

object named as

Priscilla C Hsu

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

author name string

Ava A John-Baptiste

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

E Jenny Heathcote

5

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Eric M Yoshida

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Frank H Anderson

8

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

language of work or name

0 references

publication date

30 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

2439-2448

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

https://scigraph.springernature.com/pub.10.1038/ajg.2009.346

0 references

Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Improved cognitive function as a consequence of hepatitis C virus treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

"They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Emotional distress in chronic hepatitis C patients not receiving antiviral therapy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Does cirrhosis affect quality of life in hepatitis C virus-infected patients?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Validity of the Telephone Interview for Cognitive Status (TICS) in post-stroke subjects.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Assessment of cognitive status in the elderly using telephone interviews.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Multi-attribute health status classification systems. Health Utilities Index

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

The estimation of a preference-based measure of health from the SF-36.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Modelling SF-6D health state preference data using a nonparametric Bayesian method

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Utility approach to measuring health-related quality of life

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

US norms for six generic health-related quality-of-life indexes from the National Health Measurement study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Estimation of utilities for chronic hepatitis C from SF-36 scores

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Social stigmatization and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Health-State Utilities and Quality of Life in Hepatitis C Patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.346

21 January 2018

Identifiers

10.1038/AJG.2009.346

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37536874&oldid=2120070916"